Acute myeloid leukemia (AML) is a devastating blood cancer that makes up roughly one third of all adult leukemias. It has a markedly low survival rate, rapid progression, and growing resistance to therapeutics. We are determined to understand its underlying mechanisms of resistance, and propose new treatment options.